Cargando…

Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS

PURPOSE: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomust...

Descripción completa

Detalles Bibliográficos
Autores principales: Weller, Johannes, Schäfer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Güresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich, Schneider, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325931/
https://www.ncbi.nlm.nih.gov/pubmed/35704157
http://dx.doi.org/10.1007/s11060-022-04046-z
_version_ 1784757164505563136
author Weller, Johannes
Schäfer, Niklas
Schaub, Christina
Potthoff, Anna-Laura
Steinbach, Joachim P.
Schlegel, Uwe
Sabel, Michael
Hau, Peter
Seidel, Clemens
Krex, Dietmar
Goldbrunner, Roland
Pietsch, Torsten
Tzaridis, Theophilos
Zeyen, Thomas
Borger, Valeri
Güresir, Erdem
Vatter, Hartmut
Herrlinger, Ulrich
Schneider, Matthias
author_facet Weller, Johannes
Schäfer, Niklas
Schaub, Christina
Potthoff, Anna-Laura
Steinbach, Joachim P.
Schlegel, Uwe
Sabel, Michael
Hau, Peter
Seidel, Clemens
Krex, Dietmar
Goldbrunner, Roland
Pietsch, Torsten
Tzaridis, Theophilos
Zeyen, Thomas
Borger, Valeri
Güresir, Erdem
Vatter, Hartmut
Herrlinger, Ulrich
Schneider, Matthias
author_sort Weller, Johannes
collection PubMed
description PURPOSE: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy. METHODS: The impact of obesity (BMI ≥ 30 kg/m(2)) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan–Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables. RESULTS: Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7–30.8) vs. 43.2 (32.5–54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8–18.9) vs 17.6 (14.7–20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53–4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm. CONCLUSION: Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.
format Online
Article
Text
id pubmed-9325931
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93259312022-07-28 Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS Weller, Johannes Schäfer, Niklas Schaub, Christina Potthoff, Anna-Laura Steinbach, Joachim P. Schlegel, Uwe Sabel, Michael Hau, Peter Seidel, Clemens Krex, Dietmar Goldbrunner, Roland Pietsch, Torsten Tzaridis, Theophilos Zeyen, Thomas Borger, Valeri Güresir, Erdem Vatter, Hartmut Herrlinger, Ulrich Schneider, Matthias J Neurooncol Clinical Study PURPOSE: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy. METHODS: The impact of obesity (BMI ≥ 30 kg/m(2)) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan–Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables. RESULTS: Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7–30.8) vs. 43.2 (32.5–54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8–18.9) vs 17.6 (14.7–20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53–4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm. CONCLUSION: Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients. Springer US 2022-06-15 2022 /pmc/articles/PMC9325931/ /pubmed/35704157 http://dx.doi.org/10.1007/s11060-022-04046-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Study
Weller, Johannes
Schäfer, Niklas
Schaub, Christina
Potthoff, Anna-Laura
Steinbach, Joachim P.
Schlegel, Uwe
Sabel, Michael
Hau, Peter
Seidel, Clemens
Krex, Dietmar
Goldbrunner, Roland
Pietsch, Torsten
Tzaridis, Theophilos
Zeyen, Thomas
Borger, Valeri
Güresir, Erdem
Vatter, Hartmut
Herrlinger, Ulrich
Schneider, Matthias
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
title Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
title_full Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
title_fullStr Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
title_full_unstemmed Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
title_short Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
title_sort prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of ceteg/noa-09 and glarius
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325931/
https://www.ncbi.nlm.nih.gov/pubmed/35704157
http://dx.doi.org/10.1007/s11060-022-04046-z
work_keys_str_mv AT wellerjohannes prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT schaferniklas prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT schaubchristina prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT potthoffannalaura prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT steinbachjoachimp prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT schlegeluwe prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT sabelmichael prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT haupeter prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT seidelclemens prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT krexdietmar prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT goldbrunnerroland prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT pietschtorsten prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT tzaridistheophilos prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT zeyenthomas prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT borgervaleri prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT guresirerdem prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT vatterhartmut prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT herrlingerulrich prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius
AT schneidermatthias prognosticimpactofobesityinnewlydiagnosedglioblastomaasecondaryanalysisofcetegnoa09andglarius